Download App
Help CenterSubscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Infinium Pharmachem Ltd (INFINIUM)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: INFINIUM Chemicals | Small Cap | Infinium Pharmachem Share Price

BSE Share Price
Not Listed

Infinium Pharmachem Ltd (INFINIUM)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: INFINIUM Chemicals | Small Cap | Infinium Pharmachem Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹408 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹7.8
TTM Sales
₹190 Cr.
Book Value per Share
₹77.7
P/E Ratio
33.62
Lower than its 5-year historical median
Industry PE
48
Price to Book (P/B)
3.37
Lower than its 5-year historical median
Price to Sales (P/S)
2.15
Lower than its 5-year historical median
EV/EBITDA
16.91
Lower than its 5-year historical median
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
12.32%
Outperforms industry median
Return on Capital Employed (ROCE)
13.55%
Outperforms industry median
Return on Assets (ROA)
7.61%
Operating Profit Margin
11.4%
Net Profit Margin
7.49%
Gross Profit Margin
11%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
14.26%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
31.07%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
81.12%
Asset Quality
Promoter Holding
64.91%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹105 Cr.
Equity
₹15.6 Cr.
Face Value
₹10
All Time Low / High
₹0.00 / 0.00

Infinium Pharmachem stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Very Good
Check detailed performance

Valuation

Fair

Check Valuation charts

Price Trend

Strong
Check Price chart
Q.1 Is Infinium Pharmachem Ltd a good quality company?
Infinium Pharmachem Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Infinium Pharmachem Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Infinium Pharmachem Ltd vs industry peers?
Infinium Pharmachem Ltd revenue CAGR is 21.87%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Infinium Pharmachem Ltd?
Promoters hold 64.91% of the Infinium Pharmachem Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Infinium Pharmachem Ltd over the last decade?
Over the last 3 year(s), the stock has delivered a CAGR of -3.6% based on the current price.
View More

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Infinium Pharmachem Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation ⓘ

Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % ⓘ19.9%31.8%34.4%36.8%29.3%13.2%11.2%-
Value Creation
Index ⓘ		0.41.31.51.61.1-0.1-0.2-

Growth Parameters ⓘ
Sales ⓘ3654.674101122137156156
Sales YoY Gr.-51.4%35.7%36.8%20.8%11.9%14.3%-
Adj EPS ⓘ12.45.38.37.656.36.4
YoY Gr.-154.7%117.8%57.7%-8.2%-34.5%25%-
BVPS (₹) ⓘ4.36.912.321.341.567.874.374.3
Adj Net
Profit ⓘ		12.55.48.510.67.89.710
Cash Flow from Ops. ⓘ2.36.89.17.43.1-2636-
Debt/CF from Ops. ⓘ3.81.52.53.62.5-1.80.4-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘNA23.5%15.6%14.3%
Adj EPS ⓘNA20.9%-9.1%25%
BVPSⓘNA60.7%51.5%9.5%
Share Price - - -1.9% 2.4%

Key Financial Parameters ⓘ

Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity % ⓘ		22.443.454.749.426.79.58.88.7
Op. Profit
Mgn % ⓘ		7.3911.81514.211.110.9NAN
Net Profit
Mgn % ⓘ		2.74.57.28.38.75.76.26.4
Debt to
Equity ⓘ		2.11.51.81.20.10.40.1-
Working Cap
Days ⓘ		01241381371402032030
Cash Conv.
Cycle ⓘ		0505468911271350

Valuation of Infinium Pharmachem - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Sales397199114136156190
Operating Expenses ⓘ + 36668998117139168
Manufacturing Costs1233455
Material Costs30557781103118149
Employee Cost 2324467
Other Costs ⓘ 368116117
Operating Profit ⓘ 251016191622
Operating Profit Margin (%) 6.4%7.0%10.1%14.0%13.7%10.6%11.4%
Other Income ⓘ + 1111222
Exceptional Items ⓘ 0000000
Interest ⓘ 1123243
Depreciation ⓘ 1111333
Profit Before Tax ⓘ 14913151218
Tax ⓘ 0123444
Profit After Tax 1371012814
PAT Margin (%) 2.2%3.9%6.8%8.6%8.5%5.0%7.5%
Adjusted EPS (₹)0.92.76.09.38.15.27.8
Dividend Payout Ratio (%)0%0%0%0%0%0%0%
PARTICULARSMar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 47132359109121
Share Capital ⓘ 1.021.021.025.0813.9215.5815.58
Reserves ⓘ 3612174594105
Debt +9112229114519
Long Term Debt6614108108
Short Term Debt3591933512
Minority Interest001111517
Trade Payables7121275124
Others Liabilities ⓘ 251111101613
Total Liabilities ⓘ 2234597185198175

Fixed Assets

Net Fixed Assets ⓘ +45419202423
Gross Block78824283538
Accumulated Depreciation334581114
CWIP ⓘ 0480018
Investments ⓘ 000002929
Inventories791620254439
Trade Receivables8111515203431
Cash Equivalents 1256123530
Others Assets ⓘ 3391193114
Total Assets ⓘ 2234597185198175
PARTICULARSMar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity ⓘ + 371295-2934
PBT ⓘ 14913151218
Adjustment ⓘ 2224573
Changes in Working Capital ⓘ 033-5-11-4417
Tax Paid ⓘ -0-1-2-3-4-4-4
Cash Flow From Investing Activity ⓘ + -1-5-7-5-4-27-7
Capex -1-5-5-7-4-9-10
Net Investments 00000-290
Others ⓘ 00-23-0102
Cash Flow From Financing Activity ⓘ + -1-1-2-3579-32
Net Proceeds from Shares ⓘ 000025440
Net Proceeds from Borrowing ⓘ 0000000
Interest Paid ⓘ -1-1-2-3-2-4-3
Dividend Paid ⓘ 0000000
Others ⓘ 0000-1839-29
Net Cash Flow ⓘ 1131623-5
PARTICULARSMar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)20.4348.4466.4455.0628.289.3212.32
ROCE (%)18.8932.1438.8836.7428.5713.2313.55
Asset Turnover Ratio1.732.52.131.761.741.11.02
PAT to CFO Conversion(x)32.331.710.90.42-3.632.43
Working Capital Days
Receivable Days74.6050.3049.5049.3048.3063.5062.80
Inventory Days64.9042.1047.4057.6059.8080.8080.20
Payable Days82.3062.1028.300000

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Infinium Pharmachem Ltd FAQs

The current trading price of Infinium Pharmachem on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Infinium Pharmachem stood at ₹408.4 Cr

The latest P/E ratio of Infinium Pharmachem as of 31-Dec-1969 is 40.77.

The latest P/B ratio of Infinium Pharmachem as of 31-Dec-1969 is 3.53.

The 52-week high of Infinium Pharmachem is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Infinium Pharmachem is ₹156 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Infinium Pharmachem Ltd is a good quality company.

The key valuation ratios of Infinium Pharmachem Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Infinium Pharmachem Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Infinium Pharmachem Ltd

Infinium Pharmachem is well focused to Iodine chemistry. The company is working as Contract Research and Manufacturing Services (CRAMS), but its domain is very restricted to Iodine chemistry & it revolves around Iodine derivatives or Iodination. Since 2003. the company has been manufacturing & supplying wide range of superior quality iodine derivatives & active pharmaceutical ingredient (API).

The company is also providing fully integrated customized services from R&D to Commercial scale manufacturing and packaging for its products to the Pharmaceutical, Agrochemical, Nutraceutical, Speciality Chemicals & various other chemical Industries. The company supplies range of Iodine derivatives on Order to Made basis only. The company also undertakes Non-Disclosure Agreement (NDA) for the development of confidential and rarely available Iodine compounds. 

Business area of the company

The company is engaged in manufacturing and selling of Iodian based Pharmaceutical Intermediates.

Milestones

  • 2003: Established with a vision to be a globally integrated and admired Pharmaceutical and Healthcare Company.
  • 2004: Started iodine derivatives manufacturing plant at Gujarat, India.
  • 2010: Set up R&D Unit and Certified as ISO 90001-2008.
  • 2011: Penetrated the Pharmaceutical market with the CRAMS model.
  • 2014: Upgraded Plant with GMP compliant large scale manufacturing facility.
  • 2015: Obtained FDA approval for manufacturing of APIs.
  • 2017: Certified as WHO-GMP and ISO 14001-2015.
  • 2018: Product Portfolio touched 200+ Iodine Derivatives and 7+ APIs.
  • 2019: Expanded reach to over 15+ countries across the globe.
  • 2021: Augmentation of production capacity and construction of new Premises.
  • 2022: Incorporated subsidiary company in bio-fuel segment for backward integration.
  • 2022: Conversion of the company’s status from Private Limited to Limited Company.
  • 2023: Infinium Pharmachem shares were listed on the NSE SME (Emerge) platform.
  • 2023: Subsidiary Company ‘Infinium Green Energy’, commenced Production facility from May 14, 2023.
  • 2024: Commenced construction activities for its new Project (Area comprised of around 1,114 Sq. Mt.) dedicated to manufacturing contrast media raw materials.
  • 2025: Entered into a 5-year exclusive distribution agreement with K Sakai & Company Limited
  • 2026: Successfully completed and commissioned its new manufacturing facility for contrast media raw materials at GIDC Sojitra, District Anand, Gujarat with effect from January 16, 2026.

You have 43 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now